Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Novartis Ag ADR (NY: NVS ) 109.35 +0.95 (+0.88%) Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Novartis Ag ADR < Previous 1 2 ... 5 6 7 8 9 10 11 12 13 ... 42 43 Next > Novartis' Rare Blood Disorder Therapy Scores FDA Approval December 06, 2023 The FDA approved Novartis AG's (NYSE Via Benzinga Exposures Product Safety (NVS) - Analyzing Novartis's Short Interest December 01, 2023 Via Benzinga Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V November 30, 2023 Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment... Via SBWire Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030 November 29, 2023 Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. Via SBWire Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies November 29, 2023 Tuesday, the FDA said it received reports of patients developing T-cell malig Via Benzinga Exposures Product Safety How Is The Market Feeling About Novartis? November 10, 2023 Via Benzinga Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week October 30, 2023 S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities Novartis Hikes Its Earnings Outlook For The Third Time This Year October 24, 2023 The company also beat third-quarter expectations after spinning off its Sandoz unit. Via Investor's Business Daily 3 Healthcare Stocks to Pick Up Before the Year-End Rally November 28, 2023 Explore the potential of healthcare stocks as the U.S. charges ahead with $4.3 trillion in healthcare spending Via InvestorPlace Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off November 28, 2023 Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology),... Via Benzinga Gene Therapy Market Research: Exploring Market Size, Business Growth, Career Prospects, Industry Trends, and Projections for 2028 November 27, 2023 Northbrook, IL 60062 -- (SBWIRE) -- 11/27/2023 -- In May 2022, Novartis AG (Switzerland) received US FDA approval for KYMRIAH (Tisagenlecleucel) for a third indication, including relapsed or refractory... Via SBWire Exposures Product Safety Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued. November 22, 2023 The company is working on treatments for breast cancer in a market worth $15 billion, according to the CEO. Via Investor's Business Daily 2 overlooked stocks that crushed earnings but traded lower November 20, 2023 As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results Via MarketBeat Exposures Product Safety Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal November 18, 2023 Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and... Via Talk Markets Diversifying Your Portfolio With Plant-Based Options November 16, 2023 Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market... Via Talk Markets Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On November 16, 2023 Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector. Via The Motley Fool Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030 November 14, 2023 EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END Via FinancialNewsMedia Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug November 13, 2023 Patients had big decreases in LDL cholesterol. But there were some side effects. Via Investor's Business Daily 3 Spectacular High-Yield Dividend Stocks to Buy in November November 05, 2023 Income investors should find plenty to like with these stocks. Via The Motley Fool Get Ready for Next Generation of Diabetes, Weight-Management Drugs November 01, 2023 Via Investor Brand Network Get Ready for Next Generation of Diabetes, Weight-Management Drugs November 01, 2023 EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END Via FinancialNewsMedia Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study October 30, 2023 Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patients with IgA nephropathy (IgAN). IgAN is a major cause of... Via Benzinga Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More October 28, 2023 The U.S. Via Benzinga Exposures Product Safety 3 No-Brainer Stocks to Buy for Under $100 Right Now October 28, 2023 A couple of these stocks might not be available for under $100 for too much longer. Via The Motley Fool 2 Green Flags and 1 Red Flag for Novartis Stock October 27, 2023 The Swiss pharmaceutical company just posted strong Q3 numbers and is going through some big changes. Via The Motley Fool 7 Undervalued Stocks to Buy Before Everyone Else October 26, 2023 Buy these undervalued stocks while they trade at a significant discount compared to their intrinsic valuations. Via InvestorPlace Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch October 24, 2023 Additionally, Sanofi stock has a decent 83 Composite Rating out of 99, and an 80 Earnings Per Share Rating. Via Investor's Business Daily Novartis Ag (NVS) Q3 2023 Earnings Call Transcript October 24, 2023 NVS earnings call for the period ending September 30, 2023. Via The Motley Fool Topics Earnings Exposures Financial Nano Pharmaceutical Market Next Big Move: Major Giants Abbott Laboratories, Bayer AG, Novartis AG, GlaxoSmithKline October 24, 2023 According to HTF Market Intelligence, the Global Nano Pharmaceutical market is segmented by Application (Oncology, Cardiovascular/Physiology, Antiinflammatory/Immunology, Neurology, Anti-Infective,... Via SBWire Avenue Z Hires Leading Digital Media and Technology Executive David Corchado to Lead Team in Global Strategy October 24, 2023 --News Direct-- Via News Direct < Previous 1 2 ... 5 6 7 8 9 10 11 12 13 ... 42 43 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
